LONG-TERM EFFICACY AND SAFETY OF ALISKIREN/VALSARTAN COMBINATION IN HYPERTENSIVE PATIENTS: A 54-WEEK, OPEN-LABEL STUDY

被引：0
|
作者：
Chrysant, S. G. [1 ,2 ]
Murray, A. V. [3 ]
Hoppe, U. C. [4 ]
Dattani, D. [5 ,6 ]
Patel, S. [7 ]
Zhang, J. [7 ]
机构：
[1] Oklahoma Cardiovasc & Hypertens Ctr, Oklahoma City, OK USA
[2] Univ Oklahoma, Oklahoma City, OK USA
[3] Pharmquest, Greensboro, NC USA
[4] Univ Cologne, Innere Med Klin 3, Cologne, Germany
[5] Prairie Clin Res Grp, Saskatoon, SK, Canada
[6] Univ Saskatchewan, Saskatoon, SK, Canada
[7] Nova Pharmaceut Corp, E Hanover, NJ USA
来源：
JOURNAL OF HYPERTENSION | 2009年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：S281 / S281
页数：1
相关论文
共 50 条
  • [1] Long-term tolerability and efficacy of the combination of amlodipine/valsartan in hypertensive patients: a 54-week, open-label extension study
    Philipp, Thomas
    Glazer, Robert D.
    Zhao, Yanxing
    Pospiech, Rainer
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) : 187 - 193
  • [2] Safety and Efficacy of Aliskiren/Amlodipine/Hydrochlorothiazide Triple Combination in Patients With Moderate to Severe Hypertension: A 54-Week, Open-Label Study
    Murray, Alexander V.
    Koenig, Wolfgang
    Garcia-Puig, Juan
    Patel, Samir
    Uddin, Alkaz
    Zhang, Jack
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2012, 14 (12): : 821 - 827
  • [3] Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination:: A 76-week open-label study
    Corya, SA
    Andersen, SW
    Detke, HC
    Kelly, LS
    Van Campen, LE
    Sanger, TM
    Williamson, DJ
    Dubé, S
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (11) : 1349 - 1356
  • [4] Long-term Safety and Efficacy of Etanercept in Patients With Psoriasis: An Open-label Study
    Leonardi, Craig
    Strober, Bruce
    Gottlieb, Alice B.
    Elewski, Boni E.
    Ortonne, Jean-Paul
    van de Kerkhof, Peter
    Chiou, Chiun-Fang
    Dunn, Meleana
    Jahreis, Angelika
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (08) : 928 - 937
  • [5] Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension
    Chrysant, Steven G.
    Murray, Alexander V.
    Hoppe, Uta C.
    Dattani, Dan
    Patel, Samir
    Ritter, Shannon
    Zhang, Jack
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (12) : 2841 - 2849
  • [6] Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study
    Neutel, Joel M.
    Giles, Thomas D.
    Punzi, Henry
    Weiss, Robert J.
    Li, Huiling
    Finck, Amy
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2014, 8 (12) : 915 - 920
  • [7] Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study
    Tomohiko Ishikawa
    Tatsushi Maeda
    Teruo Hashimoto
    Tetsuya Nakagawa
    Kazuhito Ichikawa
    Yasushi Sato
    Yoshihiko Kanno
    [J]. Clinical Drug Investigation, 2020, 40 : 847 - 859
  • [8] Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study
    Ishikawa, Tomohiko
    Maeda, Tatsushi
    Hashimoto, Teruo
    Nakagawa, Tetsuya
    Ichikawa, Kazuhito
    Sato, Yasushi
    Kanno, Yoshihiko
    [J]. CLINICAL DRUG INVESTIGATION, 2020, 40 (09) : 847 - 859
  • [9] Efficacy and safety of aliskiren in Japanese patients with severe hypertension: An 8 week, multicenter, uncontrolled, open-label study
    Kushiro, T.
    Le Breton, S.
    Takabayashi, N.
    [J]. JOURNAL OF HYPERTENSION, 2008, 26 : S468 - S469
  • [10] Long-Term Efficacy of Adjunctive Cariprazine in Patients With MDD: Results From an Open-Label 26-Week Safety Study
    Masand, Prakash
    Vieta, Eduard
    Waraich, Simranpreet
    Kramer, Ken
    Kerolous, Majid
    [J]. NEUROPSYCHOPHARMACOLOGY, 2023, 48 : 263 - 264
12345